• Explore /
  • Poster
  • / Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?

Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?

Abstract Poster

Authors

null

Jonathan Foote

Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC

Jonathan Foote , Laura Jean Havrilesky , Elizabeth Lin Jewell , Charlotte Gamble , Jessie Ehrisman , Gloria Broadwater , Robert L. Coleman , David E. Cohn , Angeles Alvarez Secord

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5544)

DOI

10.1200/JCO.2017.35.15_suppl.5544

Abstract #

5544

Poster Bd #

366

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

First Author: Ursula A. Matulonis

First Author: Jonathan Foote

First Author: Florian Heitz

First Author: Mansoor Raza Mirza